Delivery Order SPE2DB22D1002-SPE2DB25FLGM4
Award Date 8/18/25
Potential Completion Date 8/19/25
Potential Value $4.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $12.3K to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 13, 2025, with completion targeted for August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $5,761.47 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a $18,491.04 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is a non-set-aside procurement with an ultimate completion date of August 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,867.74 for RINVOQ ER 15 MG tablets (30-count units) on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price contract was competitively awarded without a set-aside designation and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other autoimmune conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $6,617.11 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, to be performed at the awardee's facility in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used in the treatment of rheumatoid arthritis and other inflammatory conditions. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for RINVOQ ER 15 mg tablets (30-count units) valued at $14,927.84. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under an existing contract vehicle. The order is scheduled for completion by August 26, 2025, with performance occurring at the contractor's corporate office in Conshohocken, Pennsylvania. RINVOQ is an oral Janus kinase inhibitor...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $10,006.04 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion expected by July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency awarded a $12,446.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and...